JP2023518038A5 - - Google Patents
Info
- Publication number
- JP2023518038A5 JP2023518038A5 JP2022555643A JP2022555643A JP2023518038A5 JP 2023518038 A5 JP2023518038 A5 JP 2023518038A5 JP 2022555643 A JP2022555643 A JP 2022555643A JP 2022555643 A JP2022555643 A JP 2022555643A JP 2023518038 A5 JP2023518038 A5 JP 2023518038A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- modified polypeptide
- coronavirus
- cov
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989976P | 2020-03-16 | 2020-03-16 | |
| US62/989,976 | 2020-03-16 | ||
| US202063022151P | 2020-05-08 | 2020-05-08 | |
| US63/022,151 | 2020-05-08 | ||
| US202063042907P | 2020-06-23 | 2020-06-23 | |
| US63/042,907 | 2020-06-23 | ||
| US202063089895P | 2020-10-09 | 2020-10-09 | |
| US63/089,895 | 2020-10-09 | ||
| PCT/US2021/022611 WO2021188576A1 (en) | 2020-03-16 | 2021-03-16 | Modified angiotensin-converting enzyme 2 (ace2) and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518038A JP2023518038A (ja) | 2023-04-27 |
| JP2023518038A5 true JP2023518038A5 (cg-RX-API-DMAC7.html) | 2024-02-29 |
Family
ID=75439530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555643A Pending JP2023518038A (ja) | 2020-03-16 | 2021-03-16 | 改変されたアンジオテンシン変換酵素2(ace2)またはその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230193235A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121170A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023518038A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220154796A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021239879A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022018527A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174683A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021188576A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116057176A (zh) * | 2020-03-21 | 2023-05-02 | 赖瑞克斯生物科技公司 | Ace2和补体途径的双特异性和三特异性功能分子及其用途 |
| EP3884957A1 (en) * | 2020-03-26 | 2021-09-29 | The University of British Columbia | Methods for treatment of virus and methods for screening of anti-virus reagent using organoids |
| US20230257726A1 (en) * | 2020-05-11 | 2023-08-17 | Chan Zuckerberg Biohub, Inc. | Ace2 compositions and methods |
| EP4168541A4 (en) | 2020-05-20 | 2025-04-02 | Emmune, Inc. | Ace2 muteins and methods of using the same |
| IL276627A (en) * | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
| EP4244369A4 (en) * | 2020-11-12 | 2024-10-16 | Shanghaitech University | GENOME EDITING OF IMPROVED EFFICIENCY AND ACCURACY |
| EP4426825A4 (en) * | 2021-11-01 | 2025-10-01 | Agency Science Tech & Res | RECOMBINANT/FUSION POLYPEPTIDES COMPRISING A MUTATED ANGIOTENSIN 2-CONVERTING ENZYME (ACE2) |
| WO2023081958A1 (en) * | 2021-11-11 | 2023-05-19 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Antiviral agent comprising a cellular entry receptor and fc region component |
| CN114606219B (zh) * | 2022-04-01 | 2023-10-31 | 北京大学 | 一种冠状病毒中和效应蛋白及其应用 |
| CA3257654A1 (en) * | 2022-04-13 | 2023-10-19 | Paradigm Immunotherapeutics, Inc. | METHODS OF PREVENTION OR TREATMENT OF RESPIRATORY VIRUS INFECTION, PARTICULARLY SARS-CoV-2 |
| CN117304317B (zh) * | 2022-06-28 | 2024-08-02 | 四川大学 | Ace2受体特异性结合肽及其应用 |
| EP4386084A1 (en) * | 2022-12-14 | 2024-06-19 | Formycon AG | Improved ace2 fusion proteins |
| WO2024215776A1 (en) * | 2023-04-10 | 2024-10-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Recombinant ace2 polypeptide and uses thereof |
| KR20240177843A (ko) * | 2023-06-20 | 2024-12-30 | 주식회사 엔큐라젠 | SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| CN117447609B (zh) * | 2023-10-25 | 2026-05-15 | 山西锦波生物医药股份有限公司 | 灭活冠状病毒的融合蛋白及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101961493A (zh) * | 2002-06-19 | 2011-02-02 | 大学保健网 | Ace2激活用于治疗心脏、肺和肾脏疾病及高血压 |
| US20130210726A1 (en) * | 2012-02-10 | 2013-08-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of peripheral vascular disease |
-
2021
- 2021-03-16 AU AU2021239879A patent/AU2021239879A1/en active Pending
- 2021-03-16 WO PCT/US2021/022611 patent/WO2021188576A1/en not_active Ceased
- 2021-03-16 JP JP2022555643A patent/JP2023518038A/ja active Pending
- 2021-03-16 KR KR1020227035927A patent/KR20220154796A/ko active Pending
- 2021-03-16 EP EP21717684.1A patent/EP4121170A1/en active Pending
- 2021-03-16 US US17/911,813 patent/US20230193235A1/en active Pending
- 2021-03-16 BR BR112022018527A patent/BR112022018527A2/pt unknown
- 2021-03-16 CA CA3174683A patent/CA3174683A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115244077B (zh) | 蛋白质治疗剂 | |
| IL321500A (en) | Pre-stabilized hmpv f proteins | |
| JP2023518038A (ja) | 改変されたアンジオテンシン変換酵素2(ace2)またはその使用 | |
| JP7554837B2 (ja) | 可溶性ace2及び融合タンパク質、並びにその適用 | |
| US20230174611A1 (en) | Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor | |
| CN105934249A (zh) | 用于治疗肺高压的组合物和方法 | |
| EP4217370A2 (en) | Methods and compositions for treating coronaviral infections | |
| WO2021247675A1 (en) | Coronavirus-binding agents and uses thereof | |
| JP2025170319A (ja) | Sars-cov-2阻害剤 | |
| JP2007526213A (ja) | コロナウイルスによる感染症の治療、管理および予防用の抗ウイルス剤 | |
| WO2024229151A2 (en) | Multimeric coronavirus binding molecules and uses thereof | |
| WO2022037699A1 (en) | Engineered ace2 oligomers and uses thereof | |
| US20240025972A1 (en) | Methods for modulating host cell surface interactions with sars-cov-2 | |
| TW201902920A (zh) | 重組robo2蛋白、組合物、方法及其用途 | |
| US20170198014A1 (en) | Polypeptides and their use for treating influenza | |
| CN117659181A (zh) | 针对sars-cov-2刺突蛋白的肽治疗剂 | |
| JP2024516605A (ja) | コロナウイルス感染を処置するための新規組成物及び方法 | |
| RU2837537C1 (ru) | Растворимый апф2, его слитый белок и способы их применения | |
| ZA200509512B (en) | Antiviral agents for the treatment, control and prevention of infections by coronaviruses | |
| WO2022034588A1 (en) | Compositions for diagnosis and treatment of coronavirus infections | |
| HK40107422A (en) | Methods for modulating host cell surface interactions with sars-cov-2 | |
| WO2025230768A1 (en) | Compositions and methods related to coronavirus therapies | |
| WO2022146154A2 (en) | Peptide for use in the treatment or prevention of covid-19 | |
| WO2026062244A1 (en) | COMPOSITIONS COMPRISING sTIGIT AND PD-1/PD-L1 AXIS INHIBITORS AND USES THEREOF | |
| HK40080094A (en) | Antibody and fusion protein for treating coronaviruses and use thereof |